A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT06667076 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

480

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG: Amivantamab
DRUG: Lazertinib
DRUG: Chemotherapy: Pemetrexed
DRUG: Chemotherapy: Carboplatin

Sponsor

Janssen Research & Development, LLC